People: Alexza Pharmaceuticals Inc (ALXA.O)

ALXA.O on Consolidated Issue listed on NASDAQ Global Market

2.54USD
22 Sep 2014
Price Change (% chg)

$-0.16 (-5.93%)
Prev Close
$2.70
Open
$2.65
Day's High
$2.70
Day's Low
$2.53
Volume
61,699
Avg. Vol
165,343
52-wk High
$5.93
52-wk Low
$2.50

Search Stocks

Summary

Name Age Since Current Position

Thomas King

59 2003 President, Chief Executive Officer, Director

Mark Oki

45 2012 Senior Vice President, Finance, Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer

Robert Lippe

49 2014 Chief Operating Officer, Executive Vice President - Operations

James Cassella

59 2012 Executive Vice President - Research and Development, Chief Scientific Officer

Edwin Kamemoto

61 2014 Senior Vice President - Regulatory Affairs

Michael Simms

51 2011 Senior Vice President - Operations and Manufacturing

Isaac Stein

67 2006 Lead Independent Director

J. Kevin Buchi

58 2013 Independent Director

Deepika Pakianathan

49 2004 Independent Director

J. Leighton Read

63 2004 Independent Director

Gordon Ringold

63 2001 Independent Director

Joseph Turner

62 2010 Independent Director

Biographies

Name Description

Thomas King

Mr. Thomas B. King is President, Chief Executive Officer, Director of Alexza Pharmaceuticals Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, a publicly-traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly-traded biopharmaceutical company. The Board believes that Mr. King’s position as the Company’s Chief Executive Officer and his prior experience as chief executive officer at similar companies, including a publicly-traded company, enable him to contribute to the Board his extensive knowledge of the Company and its industry and provide Board continuity. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College.

Mark Oki

Mr. Mark K. Oki, CPA (Inactive) is Senior Vice President, Finance, Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer of Alexza Pharmaceuticals Inc. He has served as Company's Vice President, Finance and Controller since February 2010, as Company's Principal Accounting Officer since May 2010 and as Company's Principal Financial Officer and Secretary since December 2011. Mr. Oki served as Company's Controller from April 2006 to February 2010. From June 2001 to April 2006, Mr. Oki served as the Controller of Pharmacyclics, Inc, a publicly-traded development stage pharmaceutical company. From 1998 to 2001, Mr. Oki held several positions, most recently as Assistant Controller, at Incyte Genomics, Inc., now Incyte Corporation, a publicly-traded company. From 1992 to 1997, Mr. Oki held several positions at Deloitte & Touche LLP, a public accounting firm. Mr. Oki received a B.S. in business administration with a concentration in accounting from San Jose State University.

Robert Lippe

Mr. Robert A. Lippe is Chief Operating Officer, Executive Vice President - Operations of the Company. From January 2011 to February 2014, Mr. Lippe served as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc. Prior to Ironwood, Mr. Lippe worked for Genentech, Inc. from 2002 to 2011. From October 2007 to January 2011, Mr. Lippe served as the Head of Manufacturing for Genentech’s Vacaville Operations. From May 2002 until October 2007, Mr. Lippe held multiple positions in strategic operations, drug substance and drug product manufacturing, and facilities. Prior to joining Genentech, Mr. Lippe spent ten years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. Mr. Lippe received his M.P.H. and M.B.A. degrees from the University of California, Berkeley, and received a B.S. degree in marine engineering from the United States Coast Guard Academy.

James Cassella

Dr. James V. Cassella, Ph.D. is Executive Vice President - Research and Development, Chief Scientific Officer of Alexza Pharmaceuticals Inc. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation, a publicly-traded biotechnology company, including Senior Vice President, Clinical Research and Development from January 2003 to June 2004. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in physiological psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

Edwin Kamemoto

Dr. Edwin S. Kamemoto, Ph.D., is Senior Vice President - Regulatory Affairs of the Company. Dr. Kamemoto has been the Company’s Vice President, Regulatory Affairs since July 2012. He joined the Company in March 2006 as Associate Director, Regulatory Affairs, and was promoted to Director, Regulatory Affairs in January 2007, to Senior Director, Regulatory Affairs in June 2008, and to Executive Director, Regulatory Affairs in January 2010. From September 2004 to March 2006, Dr. Kamemoto was a consultant for CATO Research, a contract research organization. From 1995 to 2004, he held various scientific and regulatory affairs managerial positions at Nektar Therapeutics, a publicly traded biopharmaceutical company. He also held previous scientific-related positions at Glycomed and Celtrix Pharmaceuticals, both publicly traded biopharmaceutical companies. Dr. Kamemoto received a Ph.D. in biochemistry from UCLA, completed a postdoctoral fellowship in the Department of Pharmacology at Stanford University, and received a B.S. in chemistry and biology from the University of Hawaii.

Michael Simms

Mr. Michael J. Simms is Senior Vice President - Operations and Manufacturing of Alexza Pharmaceuticals Inc. He served as Company's Senior Vice President, Operations and Quality from December 2009 to December 2011 and served as Company's Senior Vice President, Operations and Manufacturing from February 2008 to December 2009. From May 2007 to February 2008, Mr. Simms served as Senior Vice President, Manufacturing Operations and from June 2004 to May 2007 served as Vice President, Manufacturing of Nektar Therapeutics, a publicly-traded biopharmaceutical company. From August 2002 to June 2004, Mr. Simms worked as an independent consultant to develop manufacturing strategies and business plans for various early stage and small commercial stage companies. Prior to this, Mr. Simms held executive level positions at various life science companies. Mr. Simms holds an M.B.A from Pepperdine University and a B.S. in chemical engineering from the University of Missouri-Rolla.

Isaac Stein

Mr. Isaac Stein is Lead Independent Director of Alexza Pharmaceuticals Inc. He has served as a member of Company's Board since June 2001. Since November 1982, Mr. Stein has been President of Waverley Associates, Inc., a private investment firm. He is also the emeritus Chairman of the Board of Trustees of Stanford University. From 1997 to 2013, Mr. Stein served on the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company. Mr. Stein is also a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc., and The Income Fund of America, Inc. (part of the American Funds family of mutual funds). The Board believes that Mr. Stein’s tenure as a director of the Company provides continuity and experience that is important in his role as lead director. Mr. Stein also contributes relevant industry experience through his previous position as the chair of Maxygen’s board of directors and financial experience through his work with investment funds. Mr. Stein received an M.B.A. and J.D. from Stanford University and a B.A. in mathematical economics from Colgate University.

J. Kevin Buchi

Mr. J. Kevin Buchi is Independent Director of Alexza Pharmaceuticals, Inc. Mr. Buchi has served as a director, President and Chief Executive Officer of TetraLogic Pharmaceuticals Corporation, a publicly-traded biopharmaceutical company. From October 2011 until May 2012, Mr. Buchi was Corporate Vice President, Global Branded Products at Teva Pharmaceutical Industries Ltd., a publicly-traded pharmaceutical company. Prior to joining Teva Pharmaceutical Industries Ltd., Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., a publicly-traded biopharmaceutical company, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd. in October 2011. Mr. Buchi joined Cephalon Inc. in 1991 and held the positions of Chief Operating Officer and Chief Financial Officer before becoming its Chief Executive Officer. Mr. Buchi has also served on the Board of Directors of Benitec Biopharma Ltd., a publicly traded biopharmaceutical company, from April 2013 to present, and Stemline Therapeutics, Inc., a publicly traded biopharmaceutical company, from 2012 to present. The Board believes that Mr. Buchi’s experience as the chief executive officer of a pharmaceutical company with an extensive late-stage product candidate pipeline and a portfolio of branded products, his experience leading that company’s acquisition by a major international pharmaceutical company, and his experience as a director of several pharmaceutical companies offers specific expertise needed by the Company at this stage in its growth. Mr. Buchi graduated from Cornell University with a B.A. in chemistry and received a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University.

Deepika Pakianathan

Dr. Deepika R. Pakianathan, Ph.D., is Independent Director of Alexza Pharmaceuticals inc. Since 2001, Dr. Pakianathan has served as a managing member at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JPMorgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to 1998 and a post-doctoral scientist at Genentech, Inc. from 1993 to 1997. Dr. Pakianathan is also a member of the board of directors of Karyopharm Therapeutics, Inc., a publicly traded pharmaceutical company, from April 2013 to present, and OncoMed Pharmaceuticals Inc., a publicly traded biopharmaceutical company from December 2008 to present. The Board believes that Dr. Pakianathan’s experience overseeing multiple healthcare companies as a director and prior work as a biotechnology investment banker provide knowledge related to the Company’s industry sector to aid in overseeing the business development and strategy of the Company. Dr. Pakianathan received a Ph.D. in immunology and an M.S. in biology from Wake Forest University, and a M.Sc. in biophysics and a B.Sc. from the University of Bombay.

J. Leighton Read

Dr. J. Leighton Read, M.D., is Independent Director of Alexza Pharmaceuticals Inc. From 2001 until 2007, Dr. Read served as a Managing Member in four funds at Alloy Ventures, where he continues as a Venture Partner. Dr. Read founded Aviron, a biopharmaceutical company, and served as its Chairman and Chief Executive Officer until 1999 and as a director until its acquisition by MedImmune, LLC, in 2002. In 1989, Dr. Read co-founded Affymax NV, a biopharmaceutical company. Dr. Read has received several awards for co-inventing the technology underlying the Affymetrix GeneChip. The Board believes that Dr. Read’s background in founding multiple biopharmaceutical companies brings experience to assist the Company in guiding it through the processes of drug development and commercialization. Dr. Read received an M.D. from the University of Texas Health Science Center at San Antonio and completed his training in internal medicine at Duke University and the Peter Bent Brigham Hospital, and received a B.S. in psychology and biology from Rice University.

Gordon Ringold

Dr. Gordon Ringold, Ph.D., is Independent Director of Alexza Pharmaceuticals Inc. Since March 2000, Dr. Ringold served as Chairman and Chief Executive Officer of Alavita, Inc., a biotechnology company. From March 1995 to February 2000, Dr. Ringold served as Chief Executive Officer and Scientific Director of Affymax Research Institute where he managed the development of novel technologies to accelerate the pace of drug discovery. From 1997 to 2013, Dr. Ringold served as a member of the board of directors of Maxygen, Inc., a publicly-traded biopharmaceutical company, and was a member of the board of directors of Oxonica plc, a publicly-traded nanotechnology company, from 2005 to 2009. The Board believes that Dr. Ringold’s experience as both chief executive officer and director of multiple biotechnology and biopharmaceutical companies, as well as his work with technologies to advance drug discovery are important to the Company in its long-term goals to commercialize multiple products in connection with the Staccato system. Dr. Ringold received a Ph.D. in microbiology from University of California, San Francisco, in the laboratory of Dr. Harold Varmus before joining the Stanford University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from the University of California, Santa Cruz.

Joseph Turner

Mr. Joseph L. Turner is Independent Director of Alexza Pharmaceuticals, Inc. Mr. Turner currently serves on the Boards of Directors and is the chair of the Audit Committees of Corcept Therapeutics, Inc., Kythera Biopharmaceuticals, Inc. and Sophiris Bio, publicly-traded pharmaceutical companies. In 2012, Mr. Turner served on the Board of Directors and as chair of the Audit Committee of Allos Therapeutics, Inc., a publicly-traded pharmaceutical company, until its acquisition by Spectrum Pharmaceuticals Inc. in September 2012. From 2010 through 2012, he served on the Board and as a member of the Audit Committee of QLT Inc., a publicly traded biotechnology company. In 2008, Mr. Turner served as a director and member of the Audit Committee of SGX Pharmaceuticals Inc., a publicly-traded pharmaceutical company Mr. Turner served as Chief Financial Officer at Myogen, Inc., a publicly-traded biopharmaceutical company, which he joined in 1999 and served until it was acquired by Gilead Sciences in 2006. Previously, Mr. Turner was Chief Financial Officer at Centaur Pharmaceuticals, Inc. and served as Chief Financial Officer and Vice President, Finance and Administration at Cortech, Inc. Since 2009, Mr. Turner has also served on the Board of Managers of Swarthmore College and in June 2010 he was appointed to its Finance Committee, Academic Affairs Committee and Student Affairs Committee. Since June 2013, Mr. Turner has also served on its Property Committee. In 2013, Mr. Turner joined the Board of Directors of the Linda Crnic Institute for Down Syndrome at the University of Colorado Medical School. The Board believes that Mr. Turner’s background in finance and his experience in the biopharmaceutical industry make him well suited to aid the Company. Mr. Turner has an M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in molecular biology from the University of Colorado, and a B.A. in chemistry from Swarthmore College.

Basic Compensation

Name Fiscal Year Total

Thomas King

2,847,800

Mark Oki

394,280

Robert Lippe

--

James Cassella

1,101,820

Edwin Kamemoto

--

Michael Simms

980,519

Isaac Stein

--

J. Kevin Buchi

--

Deepika Pakianathan

--

J. Leighton Read

--

Gordon Ringold

--

Joseph Turner

--
As Of 30 Dec 2013

Options Compensation

Search Stocks